RET and non-small cell lung carcinoma: To date, the FDA only approved two novel drugs, Selpercatinib and Pralsetinib, as the highly selective RET inhibitors, for treatment NSCLC with RET fusion-positive, both showing an outstanding ORR of 61% and 61% in platinum-pretreated patients.37,38 In the treatment of NSCLC and other tumors, targeting RET fusion has been identified as an important aspect.